September 2017 Inhibiting mTOR, a regulatory protein complex, can prevent reactivation of latent HIV. Medications to inhibit mTOR might help people with HIV achieve and maintain undetectable HIV viral loads.
May 2015 Women who are infected with HIV and are transitioning back to communities after serving jail time are less likely than their male counterparts to have a regular HIV care provider, to take and regularly adhere to an HIV medication regimen, and to have suppression of the virus.
November 2014 Methamphetamine use and HIV infection raise the risk for functional dependence, or the need for assistance with everyday tasks. People who use methamphetamine and are HIV positive showed the highest levels of functional dependence in most domains of daily life.
October 2014 Nano-antiretroviral therapy (nano-ART) turns macrophages—one of the very cell types that HIV uses to replicate and spread through the body—into carriers for anti-HIV medications. The approach has the potential to make treatment for HIV easier and more effective.
April 2014 Intensified screening for HIV among injection drug users receiving opioid agonist therapy could prevent more than twice as many new infections as current screening practice. A recent study based on mathematical modeling found that screening every 6 months instead of annually, and adding viral RNA testing to the currently used HIV antibody testing, could improve both effectiveness and cost-effectiveness.
March 2014 Active drug use before incarceration was associated with decreased engagement in HIV treatment among HIV-infected jail detainees. The severity of drug dependence correlated with worsening measures of engagement in HIV treatment. The study concludes that evidence-based treatment for drug abuse in jails may result in improved HIV treatment outcomes, which in turn could help slow HIV-transmission rates in the United States.
January 2014 Study patients with HIV–hepatitis C coinfection progressed to successive degrees of severity of liver fibrosis 9 years sooner than those infected with HCV alone. Further findings from the study suggest that suppressing HIV with antiretroviral medications may slow HCV-related liver fibrosis.
September 2013 Dr. Marilyn Huestis of NIDA’s Intramural Research Program talks about conducting research on drug effects with human subjects, developing tests to help law enforcement identify drugged drivers, and an assay to help identify children whose prenatal exposure to anti-HIV drugs may put them at risk for adverse developmental outcomes.
Patients were more likely to take a rapid HIV test when substance abuse treatment programs offered the test onsite rather than referred for offsite testing. Patients were equally likely to accept and learn their HIV status whether the offer of onsite testing was accompanied by 30 minutes of risk reduction counseling or by 5 minutes of brief information on the testing procedure. Onsite testing accompanied by brief information was cost effective, taking into account the projected lifetime costs of treatment and the gains in health and longevity for detected cases.